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Filamentous tau inclusions are hallmarks of
Alzheimer’s disease (AD) and related tauopa-
thies, but earlier pathologies may herald disease
onset. To investigate this, we studied wild-type
and P301S mutant human tau transgenic (Tg)
mice. Filamentous tau lesions developed in
P301S Tg mice at 6 months of age, and progres-
sively accumulated in association with striking
neuron loss as well as hippocampal and ento-
rhinal cortical atrophy by 9-12 months of age.
Remarkably, hippocampal synapse loss and
impaired synaptic function were detected in 3
month old P301S Tg mice before fibrillary tau
tangles emerged. Prominent microglial activa-
tion also preceded tangle formation. Impor-
tantly, immunosuppression of young P301S Tg
mice with FK506 attenuated tau pathology and
increased lifespan, thereby linking neuroinflam-
mation to early progression of tauopathies.
Thus, hippocampal synaptic pathology and mi-
crogliosis may be the earliest manifestations of
neurodegenerative tauopathies, and abroga-
tion of tau-induced microglial activation could
retard progression of these disorders.
INTRODUCTION
Neurodegenerative diseases characterized by filamen-
tous tau inclusions are known as tauopathies, as exempli-
fied by Pick’s disease (PiD), progressive supranuclear
palsy (PSP), corticobasal degeneration (CBD), and fronto-
temporal dementia with parkinsonism linked to chromo-
some 17 (FTDP-17) (reviewed in Lee et al., 2001). Some
tauopathies are also characterized by additional filamen-
tous lesions. Thus, the hallmarks of Alzheimer’s disease(AD) and Down’s syndrome are neurofibrillay tangles
(NFTs) formed by tau filaments and extracellular fibrillar
Ab deposits (Forman et al., 2004). The discovery of over
30 tau gene mutations pathogenic for FTDP-17 showed
that tau abnormalities are sufficient to cause neurodegen-
eration, but it is unclear how tau inclusions cause neuronal
dysfunction and death.
Although tau transgenic (Tg) mice that model human
tauopathies have been generated (reviewed in Lee et al.,
2005), incipient cytotoxic effects of tau pathology are un-
known. Since the P301S tau genemutation causes rapidly
lethal and early-onset FTDP-17 (Sperfeld et al., 1999;
Bugiani et al., 1999; Yasuda et al., 2000; Morris et al., 2001;
Werber et al., 2003; Lossor et al., 2003), P301S mutant
tau Tg mice could provide insights into the onset of tauo-
pathies. While P301S Tg mice have been generated (Allen
et al., 2002; Bellucci et al., 2004), we produced P301S Tg
mice and showed that the PS19 line developed synaptic
pathology and microgliosis in hippocampus at 3 months
of age followed by synaptic dysfunction at 6 months
before neuron loss and NFT formation. Thus, synaptic
pathology and microgliosis may be the earliest manifesta-
tions of human tauopathies.
RESULTS
Generation of Human P301S and Wild-Type
T34 Tg Mice
Heterozygous Tg mouse lines expressing human wild-
type tau (line WT16) or P301S tau (lines PS5 and PS19)
were established, and their human tau protein expression
levels were approximately 5-, 3-, and 5-fold higher, re-
spectively, than endogenous mouse tau (data not shown).
Although WT16 mice did not exhibit any overt neurode-
generative phenotype up to 24 months of age, PS19
mice expressing P301S mutant tau at the same level as
wild-type tau expressed byWT16mice displayed clasping
and limb retraction when lifted by the tail (see Figure S1A
in the Supplemental Data) at 3 months of age, followed byNeuron 53, 337–351, February 1, 2007 ª2007 Elsevier Inc. 337
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ralysis at 7–10 months of age associated with a hunched-
back posture (Figure S1B) followed by an inability to feed.
Approximately 80% of the PS19 mice died by 12 months,
but median survival was 9 months. Histological analysis
of the affected muscles showed group atrophies with
small angular fibers, indicating chronic denervation of
the motor neurons (Figure S1C). The studies below focus
on the PS19 line because of its robust neurodegenerative
tauopathy phenotype.
P301S Tau Becomes Insoluble
and Hyperphosphorylated, Leading to Reduced
Microtubule Binding with Aging in PS19 Tg Mice
We analyzed soluble and insoluble tau in 1, 3, and 6month
old PS19 mice by sequential extraction of brain samples
with buffer of increasing extraction strength as described
(Ishihara et al., 1999), and we observed an age-dependent
decrease in tau solubility between 3 and 6months in PS19
mice (Figure S2A). The estimated amount of radioimmu-
noprecipitation assay (RIPA) buffer- and formic acid
(FA)- soluble fractions as percentages of the total tau in
1 month old PS19 mice were 5% and less than 0.1%, re-
spectively; they increased to 15% and 1%, respectively,
at 3 months of age, and to 30% and 10%, respectively,
at 6 months of age. The insoluble species of tau were pre-
dominantly composed of mutant human tau since they
were detected by T14, a monoclonal antibody (mAb) spe-
cific for human tau, while endogenous mouse tau was
barely detectable in the RIPA and FA fractions as illus-
trated by immunoblotting with T49, a mAb specific for
mouse tau (Figures S2B and S2C). Slower migrating tau
species in the insoluble fractions (Figure S2D, arrow)
were detected by phosphorylation-dependent mAbs
AT8 (phospho-Ser202 and phosho-Thr205), PHF1 (phos-
pho-Ser396 and phospho-Ser404), and AT270 (phos-
pho-Thr181), but not by T1, a non-phosphorylation-
dependent mAb, indicating that the FA-soluble tau in
PS19 mouse brains was highly phosphorylated, like ab-
normal tau in purified AD paired helical filaments (PHFs).
Since P301S and other tau mutants show impaired mi-
crotubule (MT) binding (Hasegawa et al., 1998; Hong et al.,
1998; Dayanandan et al., 1999; Rizzu et al., 1999), we in-
vestigated MT binding by P301S tau from Tg mouse
brains. Figure S2E shows that although all human WT
tau was recovered in the pellet fraction of WT16 Tg
mice, a significant percentage of P301S mutant tau is in
the supernatant fractions of PS19 Tg mice, and to a lesser
extent in those of PS5 Tg mice. Thus, the P301S mutation
reduces binding to MTs.
Histological Characterization of Neuropathology
in PS19 Tg Mice
The distribution of tau in PS19mice between 1–12months
was compared with the distribution in WT16 Tg mice and
non-Tg (nTg) littermates between 1–12 months of age
(Figure 1). Both young PS19 (Figures 1A, 1D, and 1F)
and WT16 (data not shown) Tg mice at 3 months of age338 Neuron 53, 337–351, February 1, 2007 ª2007 Elsevier Inc.showedweak perikaryal and dendritic tau immunostaining
(mainly in the hippocampus, amygdala, cortex, brain
stem, and spinal cord) for T14 and 17026, a polyclonal an-
tibody (pAb) to tau, but not for PHF1 (Figure 1A, insert).
However, while PS19 mice at 6 months of age showed
stronger tau-positive neuronal staining (Figure 1B), includ-
ing positivity for PHF1 (Figure 1B, insert) in the hippocam-
pus (Figure 1B), amygdala (Figure 1E), and spinal cord
(Figure 1G), older WT16 (12 month old) mice did not
show progressive accumulations of tau (Figure 1C) or
tau hyperphosphorylation (Figure 1C, insert). No apparent
neuron loss was observed in PS19 mice up to 6 months of
age, but by 8 months of age, PS19 mice showed neuron
loss in hippocampus, as well as ventricular dilatation.
This became more severe, especially in hippocampus
(Figure 1I), but also in amygdala and neocortex, and in-
cluding entorhinal cortex (Figure 1H) by 12 months of
age. Interestingly, PHF1-positive hippocampal neurons
increased with age beyond 8–10 months (Figure 1L), and
decreased thereafter in association with progressive neu-
ron loss (Figure 1K).
Since perikaryal tau accumulations increased with age
in hippocampal neurons concimmitant with a reduction in
tau immunoreactive CA3 mossy fibers (see arrowheads in
Figure 1N, and compare with Figure 1O), we asked if this
were due to loss of tau in the axons or to axonal loss. To
this end, we probed hippocampal sectionswith antibodies
to the low molecular weight neurofilament (NF) subunit (or
neurofilament light chain; NFL) (Figures 1P and 1Q). We
observed abundant NFL-positive mossy fibers in 3 month
old (arrowheads in Figure 1P), but not in 6 month old
(Figure 1Q) PS19 mice, consistent with degeneration of
CA3 mossy fibers. Moreover, 3 month old PS19 mice
showed NFL (Figure 1M) and tau-positive spheroids
(Figure 1F, arrow) in the dentate gyrus, as well as in the
cortex (Figure 1M, insert) and spinal cord white matter
(Figure 1F). These observations suggest an early defect
in axonal transport, followed by axonal degeneration.
To determine if the transport of endoplasmic reticulum
(ER) proteins was impaired, we examined calnexin (an
ER-specific chaperone) in neurons of PS19 mice. Al-
though calnexin immunoreactivity was seen in perikarya
and dendrites of hippocampal neurons of 1 month old
PS19mice (Figures S3A and S3D), dendritic immunostain-
ing decreased at 3 months of age (Figures S3B and S3E).
At 6 months of age, PS19 mice exhibited decreased cyto-
plasmic calnexin staining in neurons containing hyper-
phosphorylated tau (PHF1, green, Figures S3C and S3F),
while calnexin immunoreactivity in reactive astrocytes re-
mained unaltered (arrowheads, Figures S3C and S3F).
Thus, translocation of ER proteins is impaired in PS19
mice as young as 3 months of age, and this may reflect
early toxic effects of pathological tau prior to NFT
formation.
Brain Atrophy in PS19 Tg Mice
To characterize brain atrophy in living PS19 mice, we per-
formed magnetic resonance imaging (MRI). We showed
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Synaptic Loss and Microgliosis in P301S Tau MiceFigure 1. Neuronal Accumulation of Phosphorylated Tau, Reduced Mossy Fibers, Neuronal Loss, and Cerebral Atrophy in
PS19 Mice
The hippocampus (A–C, I–Q), amygdala (D and E), and spinal cords (F and G) from 3month old PS19 (A, D, F, M, N, and P), 6 month old PS19 (B, E, G,
O, and Q), 8 month old PS19 (L), 12 month old PS19 (H, I, and K), 12 month old WT16 (C), and 12 month old nTg (J) mice were immunohistochemically
stained with T14 (A–G), 17026 (N and O), PHF1 (inserts, A–C; L), and a pAb to NFL (P and Q), and then counterstained with hematoxylin. Neurons in 3
month old PS19 and 12 month old WT16 mice were weakly stained with T14 (A and C), and they were not positive for the phosphorylation-dependent
antibody PHF1 (inserts). Neurons in 6 month old PS19 mouse brains showed stronger tau staining (B) and were immunoreactive for PHF1 (insert in B).
Up to 8 months of age (L), the number of PHF1-positive neurons increased. Spinal cord neurons were negative for T14 in 3 month old PS19 mice (F),
whereas those in 6 month old PS19 mice were strongly positive for T14 (G). Twelve-month-old PS19 mice showed marked cerebral atrophy (H) and
neuron loss (I) compared with age-matched nTg mice (J). Most remaining neurons were not PHF1-positive (K). Spheroids positive for tau (F) and NFL
(M) are present in spinal cord (arrow, F), hippocampus (arrows, M), and cortex (insert in M) in PS19 mice at 3 months of age. Although mossy fibers in
hippocampus of 3 month old PS19 mice were tau immunoreactive (arrowheads, N), this staining is lost in 6 month old PS19 mouse brains (O); this is
accompanied by a concomitant decrease in NFL immunostaining in 6 month old PS19 mice (Q), but not in 3 month old PS19 mice (arrowheads, P).
Scale bars: 10 mm (A–E, I–M); 50 mm (F and G); 500 mm (H); 100 mm (N–Q).Neuron 53, 337–351, February 1, 2007 ª2007 Elsevier Inc. 339
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Synaptic Loss and Microgliosis in P301S Tau Micethat there was striking ventricular dilatation in 9 month old
PS19 mice, as evidenced by low-intensity areas in the T1-
weighted image (Figure 2A) and high-intensity areas in the
T2-weighted image (Figure 2B), with marked hippocampal
and neocortical atrophy compared with nTg mice (Figures
2C and 2D). Volumetric analysis in nTg and PS19 mice at
6, 9, and 12months of age indicated a 20% volume reduc-
tion in cerebral cortical volume at 12 months of age and
25% and 45% volume reductions in the hippocampus
at 9 and 12 months of age, respectively (Figures 2E and
2F). This suggests that brain atrophy in PS19 mice pre-
dominantly occurs in limbic regions, as seen in AD brains.
We next quantified the number of neurons spanning the
pyramidal cell layer of the hippocampal CA3 region in
PS19 mice using digital photomicrography. Consistent
with our initial histological findings, a striking reduction
in the number of neurons was observed in 12 month old
PS19 mice (107 ± 35/slice and 368 ± 84/slice in PS19
and nTg mice, respectively; p < 0.01 by t test; n = 4 in
each group). However, there was no significant neuron
loss in 6 month old PS19 and nTg mice (312 ± 31/slice
and 344 ± 61/slice in PS19 and nTg mice, respectively;
p > 0.05 by t test; n = 4 in each group). Taken together,
these data indicate that prominent neuronal death in the
hippocampus of PS19 mice begins at 9 months of age.
NFT Formation in PS19 Tg Mice
To determine if tau inclusions adopt structures similar to
authentic human NFTs, we examined sections of brain
and spinal cord from 6 month old PS19 mice with Gallyas
silver (Figures 3A–3D), thioflavin S (Figure 3E) and Congo
red stains (Figure 3E, insert). Even at low magnifications
Gallyas-stained neuronal NFTs were evident in neocortex,
amygdala, hippocampus (Figure 3A), and other CNS re-
gions, including brain stem and spinal cord (Figure 3A in-
sert); these NFTs were first visualized by Gallyas staining
at 5 months of age. Although a few inclusions could be
seen at 9 months of age in a lower-expression line, PS5,
no inclusions were observed in WT16 mice up to 24
months of age (data not shown). Gallyas-positive inclu-
sions (Figure 3E), including thread-like structures (Fig-
ure 3E, arrowheads), were also thioflavin S and Congo
red positive. NFTs were morphologically heterogeneous,
as exemplified by flame-shaped (Figure 3D) or globose-
shaped (Figure 3C) NFTs, but none resembled the Pick
bodies seen in PiD. Comparison of Gallyas-stained tan-
gles in hippocampus (Figure 3B) and amygdala (Figure 3C)
with tau staining in the same regions showed that tau-
positive inclusions were similar to the Gallyas-positive
lesions. Notably, Gallyas methods and anti-tau immuno-
histochemistry detected dot-like profiles in hippocampal
sections from old PS19 mice (Figure 3D, arrowheads
and insert), which were also immunolabeled by antibodies
to synaptophysin and a-synuclein (data not shown), sug-
gesting that some tau pathology accumulated at presyn-
aptic sites. This synaptic localization was also as con-
firmed by immuno-electron microscopy (EM) using an
anti-tau antibody (see below).340 Neuron 53, 337–351, February 1, 2007 ª2007 Elsevier IncMicroglial Activation Antecedes Astrogliosis
in Regions of PS19 Brains with NFTs
Since gliosis parallels the distribution and density of NFTs
and/or neuronal loss in tauopathies (Arriagada et al., 1992;
Togo and Dickson, 2002; Muramori et al., 1998; Bierer
et al., 1995; Harpin et al., 1990), we probed PS19 mouse
brains with antibodies to glial fibrillary acidic protein
(GFAP). Weak GFAP staining was seen throughout brain
and spinal cord, especially in white matter, of 3 month
old PS19 mice (Figure 4A), while markedly increased
GFAP staining was observed in white and gray matter of
hippocampus, amygdala, entorhinal cortex, and spinal
cord in 6month old PS19mice (Figures 4B and 4C) relative
to age-matched WT16 Tg mice (Figure 4D). Significantly,
the distribution and density of NFTs (Figure 3A) corre-
sponded closely with that of the astrogliosis (Figure 4B),
Figure 2. Quantification of Progressive Brain Volume Reduc-
tion in Living PS19 Mice
In vivo T1-weighted gradient-echo (A andC) and T2-weighted RARE (B
and D) coronal MRI images illustrate remarkable atrophy of hippocam-
pus and entorhinal cortex plus ventricular dilatation in a 9 month old
PS19 mouse (A and B) compared with an age-matched nTg control
(C and D). Quantitative analysis of the cortical (E) and hippocampal
(F) volume data reveals that the hippocampus is a primary site of neu-
ronal loss in the PS19 mice, beginning at 9 months of age. The hippo-
campal volume profoundly declined by approximately 50% at 12
months of age. *p < 0.001 by Bonferroni’s multiple comparison follow-
ing two-way ANOVA..
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Synaptic Loss and Microgliosis in P301S Tau MiceFigure 3. Intraneuronal Tau Amyloid Formation in the CNS of PS19 Mice
Brain and spinal cord (insert, A) sections of 6 month old PS19mice were stained with Gallyas silver impregnation (A–D), thioflavin S (E) and Congo red
(insert, E). Widespread Gallyas-positive NFT-like inclusions are evident (A), similar to tau-labeled pathologies in hippocampal CA3 (B) and amygdala
(C). Punctate Gallyas-positive profiles also are seen at a high magnification (blue arrowheads, D), similar to the staining by the anti-tau pAb 17026
(insert). NFT-like inclusions are stained with thioflavin S and Congo red (insert), as are thread-like structures (E, arrowheads) resembling their human
counterparts. Scale bars, 500 mm (A); 100 mm (insert of A); 10 mm (B–E).although the most striking astogliosis occurred in white
matter (Figures 4B and 4C) where little tau pathology
was seen (Figures 3A and 3B), suggesting that this reflects
degeneration of white matter axons projecting from
tangle-bearing neurons.
Since microglia-mediated neuroinflammation is impli-
cated in mechanisms of neurodegenerative diseases in-
cluding tauopathies (Akiyama et al., 2000), we examined
microglial activation using several different antibodies to
microglial antigens, including HLA-D (Figures 4E and
4F), HLA-DR (Figures 4G and 4H), and CD11b (Figures
4I and 4J). Although nTg mice showed minimal staining
(Figures 4F, 4H, and 4J), 8 month old PS19 mice exhibited
increased microglial staining, especially in hippocampus
(Figure 4E), amygdale, and entorhinal cortex, which paral-
leled the distribution of NFTs and astrogliosis. Surpris-
ingly, younger PS19mice (3–4months old), which showed
no overt astrogliosis (Figure 4A), also showed microglial
activation mainly in the hippocampal region (Figure 4G),
characterized by a bushy, thickened, and branched pro-
cesses (Figure 4G, insert). To quantify the microglial acti-
vation in the brains of PS19 mice, we used [3H]DAA1106,
a radiotracer for microglia (Zhang et al., 2003; Maeda
et al., 2004). Radiograms of PS19 mouse brains clearly
showed an age-dependent microglial activation, espe-
cially in hippocampus, amygdala, and entorhinal cortex
(Figures 4T–4V) relative to nTg mice (Figure 4S). Quantita-
tive analysis demonstrated significantly enhanced binding
of microglial tracer in the hippocampus (Figure 4W) and
entorhinal cortex (Figure 4X) of the PS19 mice that in-
creased from 3–9 months of age, consistent with the
microglia-specific antibody studies.NAdditionally, we assessed levels of neuroinflammatory
markers in hippocampal neurons (Figure 4 and Figure 5).
In 12 month old PS19 mice, the majority of neurons in hip-
pocampal regions were immunoreactive for interleukin-1b
(IL-1b) (Figure 4M and 4N) and cyclooxygenease-2 (cox-2)
(Figure 5K). The immunoreactivity for these markers was
most intense in pyramidal cells, but these markers were
barely detectable in nTg mice (Figures 4O, 4P, and 4R).
Notably, intense IL-1b (arrowheads in Figure 4K and
higher power image in Figure 4L) and cox-2 (Figure 4Q)
immunoreactivities in 4 month old PS19 mice were seen
primarily in the CA3 regions. These observations provide
direct evidence that pathological neuroinflammatory
changes antecede the development of NFTs in the hippo-
campus of PS19 mice.
Sincemicroglial activation is one of the earliest brain pa-
thologies in PS19 mice, we probed potential mechanistic
links between activation of microglia and the progression
of tau pathology by immunosuppressing PS19 mice with
FK506, beginning at 2 months of age (Figure 5). Although
only 20% of untreated PS19 mice (n = 35) survived to
12 months of age, 60% of FK506-treated mice (n = 19)
survived the length of the observation period (Figure 5S;
p < 0.03 by log rank statistic for the difference between
untreated and treated mice). Significantly, a subset of the
treated PS19 mice showed no overt hippocampal atrophy
(Figures 5A and 5B) and negligible tau pathology (Figures
5C–5F). Neuroinflammation markers such as HLA-DR
(compare Figure 4G and Figure 5G), CD11b (compare
Figure 4I and Figure 5H), cox-2 (Figures 5I–5L), and IL-
1b (Figures 5M–5P) were dramatically attenuated in the
treated PS19 mice. Moreover, there was a markedeuron 53, 337–351, February 1, 2007 ª2007 Elsevier Inc. 341
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Synaptic Loss and Microgliosis in P301S Tau MiceFigure 4. Progressive Microglial Activation and Astrogliosis in the CNS of PS19 Mice
The brain and spinal cord (inserts) of PS19, WT16 (D) Tg, and nTg (F, H, J, O, P, and R) mice were stained with a pAb to GFAP (A–D), mAb to HLA-D
(E and F), mAb to HLA-DR (G and H), mAb to CD11b (I and J), pAb to IL-1b (K–P), and pAb to cox-2 (Q and R). Gliosis revealed by GFAP staining is
dramatically increased in 6 month old (B) compared with 3 month old (A) PS19 mice, especially in hippocampus, amygdala, cortex, and spinal cord
(inserts), which parallels NFT-like inclusions (see Figure 3). Higher magnification shows reactive astrocytes in CA3 of a 6 month old PS19mouse brain
(C), while fewer reactive astrocytes are seen in the same region of a 6month oldWT16mouse brain (D). Activatedmicroglia stainedwith HLA-DR (G) or
CD11b (I) occur in PS19mice as early as at 3–4months of age, especially in hippocampus (E, 8months old). Themicroglial responsewas quantified by
autoradiography as described in the text. Unlike nTg mice (S), PS19 mice showed increasing microglial activation primarily in the hippocampus and
entorhinal cortex from 3 to 9 months (T–V). Measurement of specific binding of the radiotracer in the hippocampus (W) and entorhinal cortex (X) is
indicative of elevated microglial activity in PS19 mice emerging at 3 months of age. Control 12 month old nTg mice showed no or faint staining for
IL-1b (O and P), but IL-1b-immunoreactive neuronswere primarily localized to theCA3 region in 4month old PS19mice (K, arrowheads). A high-power
photomicrograph indicates heterogeneity of IL-1b expression among CA3 cells, with intense staining in neurons (L). Cox-2 immunoreactivities are
dramatically increased in CA3 neurons of 4 month old PS19 mice (Q) relative to age-matched nTg controls (R). *p < 0.05; **p < 0.001 by Bonferroni’s
multiple comparison following two-way ANOVA. Scale bars: 500 mm (A and B); 50 mm (inserts in A and B; C andD); 200 mm (E and F); 100 mm (K,M, and
O); 20 mm (G–J, L, N, P, Q, and R).342 Neuron 53, 337–351, February 1, 2007 ª2007 Elsevier Inc.
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Synaptic Loss and Microgliosis in P301S Tau MiceFigure 5. Attenuated Mortality, Inflammatory Responses, and Tau Pathology in PS19 Tg Mice Treated with FK506
H&E sections (A and B) at low magnification show amelioration of hippocampal atrophy in a 12 month old PS19 mouse after 10 months of oral FK506
treatment (B) compared with an age-matched untreated PS19mouse (A). AT8 immunostaining in hippocampal CA3 (C and D) and CA1 (E and F) dem-
onstrates that tau pathology in the 12month old PS19mouse with FK506 treatment was greatly attenuated (D and F). Higher magnification of the CA3
region reveals that severe neuronal loss in the PS19 mice (C and E) was dramatically halted by FK506 (D and F). HLA-DR- (G) and CD11b-positive (H)
microglial cells were barely detected in PS19 mice treated with FK506. Expressions of cox-2 (I–L) and IL-1b (M–P) in CA3 pyramidal neurons were
suppressed in 8 (J and N) and 12 (L and P) month old PS19 mice treated with FK506 compared with age-matched untreated PS19 mice (I, K, M,
and O). Analysis of tau protein solubility showed decreased highly phosphorylated FA-soluble tau in 12 month old PS19 mice treated with FK506
compared with 12 month old untreated PS19 mice (Q, arrow), and less tau phosphorylation in FK506-treated PS19 mice (R). Kaplan-Meier plots
(S) demonstrate that FK506 significantly extends survival of PS19 mice. **p < 0.03 by log rank statistics. Scale bars: 150 mm (A and B); 10 mm (C–P).suppression of neuronal loss in CA3 region of FK506-
treated 12 month old PS19 mice (244 ± 37/slice and
107 ± 35/slice for treated and untreated mice, respec-tively; p < 0.01 by t test; n = 4 in each group) and a concom-
itant reduction in the amount of insoluble hyperphos-
phorylated tau in FA fractions (arrow in Figure 5Q). TheNeuron 53, 337–351, February 1, 2007 ª2007 Elsevier Inc. 343
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Synaptic Loss and Microgliosis in P301S Tau MiceFigure 6. EM Reveals Tau Filament Accumulation in Cytoplasm and Synapses, Decreased Mitochondria and ER, and Axonal and
Neuronal Degeneration
Transmission EM (A–E and K) and immuno-EM (insert in E; F–J) of spinal cord (A–D) and hippocampus (E–K) from PS19 (A, C, and E–K) and WT16 (B
and D) Tgmice. Abundantmitochondria and well-developed ER are seen in neuronal perikarya ofWT16mouse brains (B and D), but mitochondria and
ER are diminished (A and C), and some mitochondria are swollen in neurons of PS19 mouse brains (arrowhead, C). Higher magnification of CNS neu-
rons in PS19mice shows abundant filaments (C and E) 12–20 nm in diameter and immunolabeled by 17026, the pAb to tau (insert, E). In the CA3 region
of the PS19 mouse brain, postsynaptic (F and H) and presynaptic (G) tau filament accumulation is evident by immuno-EM (F–H), concomitant with
ongoing axonal degeneration (I and J), though neuronal degeneration also occurred in the absence of filamentous aggregates (K). Scale bars:
2 mm (A and B); 500 nm (C, D, I, and J); 100 nm (F–H); 1 mm (K).percentage of the tau in FA fractions in terms of total tau
was 8.6% ± 1.9% in untreated PS19 mice and 3.8% ±
3.8% in FK506-treated PS19 mice (n = 5 in each group,
p < 0.05). Soluble tau was also less phosphorylated in
FK506-treated compared with nontreated PS19 mice
(Figure 5R). Thus, these data suggest a mechanistic link
between aberrant microglia activation and progression
of tau pathologies.
Ultrastructural Analysis of Pathology
in PS19 Tg Mice
To investigate the ultrastructure of NFT-like inclusions,
transmission EM (Figures 6A–6E and 6K) and immuno-
EM studies of tau (Figure 6E, insert, and Figures 6F–6J)
were performed. Spinal cord motor neurons (Figures 6A
and 6C) and hippocampal pyramidal neurons (Figure 6E)
in 6 month old PS19 mice harbored filamentous cytoplas-
mic aggregates similar to authentic human tau tangles
found in AD and tauopathy brains (Figures 6A, 6C, and
6E), while neurons in the WT16 mice did not show any ab-
normal tau filaments (Figures 6B and 6D). The randomly
oriented filaments in the NFT-like inclusions of the older
PS19 mice were 12–20 nm in diameter (Figures 6C and
6E) and immunolabeled with 17026, a pAb to tau (Fig-
ure 6E, insert). Similar aggregates of filamentous tau
also were seen in synapses (Figures 6F–6H), including
postsynaptic (Figures 6F and 6H) as well as presynaptic344 Neuron 53, 337–351, February 1, 2007 ª2007 Elsevier Inc(Figure 6G) sites, and these aggregates probably corre-
spond to the dot-like tau-positive and Gallyas-stained
profiles in hippocampus. Degenerating axons (Figures 6I
and 6J), some of which contained aggregated tau-positive
filaments (Figure 6J), were observed in the same CNS re-
gions, and occasionally, degenerating neurons with an
electron-dense cytoplasm and nucleus were present
(Figure 6K). Finally, comparedwithWT16 neurons (Figures
6B and 6D), PS19 neurons showed reduced ER, dimin-
ished numbers of mitochondria (Figures 6A and 6C), and
abnormally swollen mitochondria (Figure 6C, arrowhead).
Synaptic Pathology Is an Early Manifestation
of Neurodegeneration in PS19 Tg Mice
Neurodegeneration usually begins in distal axonal seg-
ments, and progresses proximally in a dying-back pro-
cess to culminate in the death of affected neurons. To de-
termine if neurodegeneration in the PS19 mice precedes
NFT formation, we examined synapses emanating from
dentate gyrus neurons that terminate in the CA3 region
for evidence of early synaptic pathology. Immunohisto-
chemical studies with antibodies to synaptophysin (Fig-
ures 7A–7D) and a-synuclein (SNL1, Figures 7E–7H) of
presynaptic terminals showed that both antibodies in-
tensely stained the synapse-rich granular layer of CA3 in
a 6month old nTgmouse (Figures 7A and 7E). While a sim-
ilar pattern also was seen in a 1month old PS19 Tgmouse.
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The CA3 region of hippocampus from 6 month old nTg mice (A, E, and I), 12 month old WT16 mice (insert, A), and 1 (B, F, and J), 3 (C, G, and K) and 6
(D, H, and L) month old PS19 Tg mice immunostained for synaptophysin (A–E) shows synaptic changes in PS19 mice. As seen in nTg mice (A), 12
month old WT16 (insert, A) and 1 month old PS19 (B) mice display normal synaptophysin staining in CA3, but synaptophysin staining in CA3 is dra-
matically reduced in 3 (C) and 6 (D)month old PS19mice. Double immunofluorescence labeling with antibodies to a-tubulin (green) and synuclein (red)
demonstrated that the a-synuclein immunostaining decreased with age in PS19 mice ([G], 3 months; [H], 6 months) relative to 6 month old nTg (E),
while slight changes in a-tubulin staining are observed in PS19 mice. Postsynaptically localized GluR2/3 immunoreactivity in PS19 mice mildly de-
clined at 6 months of age (L) compared with 6 month old nTg (I), and was prominently reduced at 9 months of age (insert, L). Scale bars: 10 mm.(Figures 7B and 7F), the immunoreactivity for synaptophy-
sin decreased progressively in the PS19 Tg mice from 3
(Figures 7C and 7G) to 6 (Figures 7D and 7H) months of
age. In contrast, no alterations were seen in CA3 of
WT16 tau Tg mice, even at 12 months of age (Figure 7A,
insert). When compared with nTg mice (Figure 7E), double
immunofluorescence labeling with antibodies to a-tubulin
(green) and a-synuclein (red) demonstrated a prominent
decrease of a-synuclein and only slight changes of a-
tubulin in the PS19mice from 3 (Figure 7G) to 6 (Figure 7H)
months of age. Moreover, immunoreactivity for GluR2/3,
a postsynaptic receptor, also decreased progressively
from 6 (Figure 7L) to 9 (Figure 7L, insert) months in the
PS19 mice.
Synaptic Plasticity Is Severely Impaired
prior to Neuronal Loss in PS19 Tg Mice
To investigate functional correlates of synaptic degenera-
tion observed in 6 month old PS19 mice, we performed
in vivo electrophysiological analysis using 6 month old PS19
and nTg mice. We first examined basal synaptic transmis-
sion by stimulating Schaffer collaterals at increasing inten-
sities and generating input/output curves from measures
of fiber volleys and field excitatory postsynaptic potentials
(fEPSPs) elicited in CA1. Six-month-old PS19 mice ex-
hibited smaller fiber volley amplitude, fEPSP slopes, and
amplitudes at all stimulus intensities tested, and hadsignificantly reduced maximum fEPSPs relative to nTg
mice, while fEPSP slopes in PS19 and nTgmice were sim-
ilar when plotted against fiber volley amplitude (Figures
8A1–8A3). These data indicate that synaptic conduction
in a baseline condition is impaired in the PS19 mice by 6
months of age, presumably due to reduced number of fir-
ing fibers. We next assessed presynaptic function by
quantifying paired-pulse facilitation (PPF) ratio. The
PS19 mice exhibited significantly reduced PPF ratio at
all interstimulus intervals (Figure 8B), demonstrating evi-
dent presynaptic dysfunction in the CA1 region. Finally,
long-term potentiation (LTP) in the CA1 hippocampal re-
gion, which is thought to represent learning and memory,
was significantly deteriorated in the PS19 mice, providing
strong evidence of attenuated postsynaptic responsive-
ness and compromised synaptic plasticity (Figures 8C1
and 8C2). As the difference in LTP decay gradually be-
came notable toward the late phase of the observation,
it is conceivable that perturbed LTP in PS19mice is a con-
sequence of prominent attenuation of late-LTP accompa-
nied by a modest diminution of intermediate-LTP.
Taken together with the immunohistochemical findings
showing synaptic pathology but no overt reduction in the
number of hippocampal neurons in 6 month old PS19
mice, these electrophysiological data support the idea
that synaptic deterioration antecedes neuron loss as
well as NFT formation.Neuron 53, 337–351, February 1, 2007 ª2007 Elsevier Inc. 345
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Stimulus-response curves of field excitatory postsynaptic potential (fEPSP) slopes (A1) and fiber volley amplitude (A2) versus stimulus at the Schaffer
collateral-CA1 synapses in the hippocampus of 6 month old nTg and PS19mice illustrate impaired basal synaptic transmission in the PS19mice. The
synaptic response was significantly reduced in the PS19mice relative to the nTgmice (F = 4.229, p = 0.04 for main effect of genotype on fEPSP slope;
and F = 3.151, p = 0.001 for interaction between stimulus intensity and fiber volley amplitude, by repeated-measures two-way ANOVA). Insets in (A2)
show representative fEPSP traces in response to different stimulus intensities (arrow indicates fiber volley). Scatterplot of fEPSP slope against fiber
volley amplitude (A3) indicates no significant difference between two genotypes (p > 0.05 by repeated-measures two-way ANOVA). In analyzing
short-term synaptic plasticity by comparing PPF (B), paired-pulse ratio measured at different interstimulus intervals was significantly decreased in
the PS19 mice as compared with the nTg mice (F = 7.661, p = 0.013 by repeated-measures two-way ANOVA), indicating compromised presynaptic
release probability at the Schaffer collateral-CA1 synapses. Insets show representative fEPSP traces in response to paired-pulse stimuli. Moreover,
the PS mice exhibited a significantly diminished magnitude of long-term potentiation (LTP) (C1), particularly in a late stage of the measurement
program (F = 10.155, p = 0.006 by repeated-measures two-way ANOVA for data between 75 and 85 min) (C2), implying attenuated postsynaptic
responsiveness. Insets show representative fEPSP traces just before tetanus (black lines) and 70 min after (gray lines). Horizontal and vertical
bars represent SE.DISCUSSION
Diverse FTDP-17 mutant andWT tau-expressing Tg mice,
worms, and flies model tau pathologies and behavioral346 Neuron 53, 337–351, February 1, 2007 ª2007 Elsevier Inc.manifestations of AD and related tauopathies, thereby
providing opportunities to elucidate mechanisms of neu-
rodegeneration in human tauopathies (reviewed in Lee
et al., 2005). Suppressing human mutant tau in inducible
Neuron
Synaptic Loss and Microgliosis in P301S Tau MiceTg mice improved memory function and attenuated neu-
ron loss despite the presence of NFTs (Santacruz et al.,
2005; Ramsden et al., 2005), suggesting that other pathol-
ogies drive neuronal dysfunction and degeneration. While
a number of mechanisms have been proposed to account
for neurodegeneration triggered by tau abnormalities (Lee
et al., 2001; Zhang et al., 2004, 2005; Roy et al., 2005), the
earliest pathological events that initiate neuron dysfunc-
tion and death in tauopathies are not understood. Thus,
the importance of this study goes well beyond demon-
strating that PS19 mice develop the hallmark tau lesions
of human tauopathies, since we detected synaptic pathol-
ogy andmicroglial activation as the earliest manifestations
of disease months before the formation of NFTs.
Thus, by demonstrating a loss of synaptic integrity at 3
months of age and synaptic dysfunction at 6 months in the
PS19 mice, we provide compelling evidence implicating
synaptic pathology, in addition to concomitant microglial
activation, as the earliest neurotoxic consequences of
pathogenic human tau expression culminating in progres-
sive neurodegeneration. Despite correlations between
NFTs, neuronal loss, and dementia in AD (Fukutani et al.,
2000), it still is not clear if NFTs initiate disease onset
(Kril et al., 2002; Bussiere et al., 2003), and it has been pro-
posed that synaptic loss correlates more robustly with
cognitive deficits in AD than does the burden of plaques
or tangles (Davies et al., 1987; Terry, 1991; Masliah,
2001; Price et al., 2001; Selkoe, 2002). Moreover, synaptic
damage also has been reported in other tauopathies
(Bigio et al., 2001; Lipton et al., 2001; Suzuki et al., 2002).
Thus, our studies of the PS19 tau Tg mice provide novel
insights into the earliest manifestations of disease onset
in neurodegenerative tauopathies.
Since one of the most obvious early synaptic abnormal-
ities in PS19 Tg mice was the formation of tau aggregates
at the synaptic compartment, it is notable that similar syn-
aptic tau aggregates also have been observed in the AD
brain (Su et al., 1997). Notably, the accumulation of this
synaptic tau pathology could reflect detachment of mu-
tant P301S tau from MTs in axon terminals, which could
destabilize MTs and deleteriously affect transport focally
at synapses (Roy et al., 2005). Indeed, a reduction in the
ability of tau to bind MTs is a well recognized loss of func-
tion caused by the P301S mutation (Hong et al., 1998;
D’Souza et al., 1999; Murrell et al., 1999; Rizzini et al.,
2000; Lee et al., 2001). Since synapses are more distal
from the perikaryal protein synthetic machinery than any
other neuronal compartment, synapses are highly vulner-
able to impairments in transport of essential cargo below
a critical threshold; this notion is supported by the obser-
vation of axonal spheroids and decreased dendritic ER in
the PS19 mice as early as 3 months of age.
Further, we demonstrated that microglial activation also
is an early manifestation of neurodegenerative tauopa-
thies, which is consistent with correlative studies of AD
(Akiyama et al., 2000) and related tauopathies (i.e., PSP,
CBD). Indeed, recent tau Tg mouse studies suggest mi-
croglial activation is linked to tau deposition (BellucciNet al., 2004; Ikeda et al., 2005), and inflammatory re-
sponses may exacerbate tau pathology (Li et al., 2003;
Kitazawa et al., 2005). Significantly, we provide experi-
mental evidence linking microglial activation to tau pathol-
ogies in the hippocampus of FK506-treated PS19 mice,
and recent in vitro studies (Takeuchi et al., 2005) suggest
that activated microglia interfere with neuronal transport
by damaging dendrites and axons, thereby exacerbating
the deleterious consequences of tau pathologies on intra-
neuronal transport.
In summary, we have identified synaptic pathology and
microglial activation as the earliest manifestations of neu-
rodegenerative tauopathies, and provide experimental
evidence linking early microglial activation to the pro-
gression of tau pathology. Hence, it is plausible that
neurodegenerative tauopathies could be ameliorated by
pharmacological modulation of neuroinflammation.
EXPERIMENTAL PROCEDURES
Tau Tg Mice
A cDNA construct of theWT human T34 isoform tau (1N4R), consisting
of exons 1 to 13 without exon 3, and the same cDNA harboring the
P301S mutation were cloned into the MoPrP.Xho expression vector
containing the mouse prion (MoPrP) promoter (Borchelt et al., 1996)
at the XhoI site. A 15 kb NotI fragment containing T34 and the MoPrP
promoter, together with its 39 untranslated sequences, was used as
the transgene to create tau Tg mice on a B6C3H/F1 background. Ge-
nomic DNA samples were isolated from mouse tails with Puregene
DNA isolation kits (Gentra System, Minneapolis, MN). Potential
founders were identified by Southern blot analysis with a [32P]-labeled
T34 probe. Stable Tg lines carrying the WT (line WT16) or the mutant
P301S (lines PS5 and PS19) human T34 transgenes were established.
Tg and nTg offspring were identified by Southern blot analysis of
tail DNA.
Western Blot Analysis
Tau protein levels were determined by homogenizing brains in 2 ml/g
tissue of ice-cold high-salt reassembly buffer (RAB-HS) (0.1 M MES,
1 mM EGTA, 0.5 mM MgSO4, 0.75 M NaCl, 0.02 M NaF, 1 mM
PMSF, and 0.1% protease inhibitor cocktail), followed by centrifuga-
tion at 50,000 3 g for 40 min at 4C in a Beckman TL-100 ultracentri-
fuge. Protein concentrations were determined and SDS-PAGE, fol-
lowed by western blot analysis, was performed as described (Hong
et al., 1998; Ishihara et al., 1999; Zhang et al., 2004, 2005).
Tau Protein Solubility and Phosphorylation States
Proteins were extracted from brains using RAB-HS as described
above. The RAB-HS-insoluble pellets were rehomogenized with 1 M
sucrose in RAB and centrifuged at 40,000 3 g for 20 min at 4C to
remove myelin and associated lipids. The resulting pellets were dis-
solved with 1 ml/g tissue in RIPA (50 mM Tris, 150 mM NaCl, 0.1%
SDS, 0.5%sodiumdeoxy-cholate, 1%NP40, and 5mMEDTA [pH 8.0])
and centrifuged at 40,0003 g for 20min at 4C. The supernatants were
used as RIPA-soluble samples, while the RIPA-insoluble pellets were
extracted with 70% FA to recover highly insoluble protein. Quantitative
western blot analyses were performed as described (Bramblett et al.,
1992, 1993; Hong et al., 1998; Ishihara et al., 1999; Zhang et al.,
2004, 2005).
Immunohistochemical and Histochemical Studies
Mice were deeply anesthetized and transcardially perfused with 15 ml
of phosphate-buffered saline (PBS), and brains and spinal cords were
removed, followed by immersion fixation for 24 hr with 10% formalin ineuron 53, 337–351, February 1, 2007 ª2007 Elsevier Inc. 347
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Zhang et al., 2004, 2005). Six-micrometer paraffin sections of brains
and spinal cords were immunostained using streptavidin-biotin-perox-
idase as well as double- and triple-labeling immunofluorescence
methods (Ishihara et al., 1999; Zhang et al., 2004). For immunostaining
microglia, 20 mm thick sections fixed with 4% paraformaldehyde were
used (Yoshiyama et al., 2000) while Gallyas silver, thioflavin S, and
Congo red methods were used to detect fibrillary tau lesions.
To derive unbiased estimates of neuronal loss in the hippocampal
CA3 region of PS19 Tg mice at 6 and 12 months of age, coronal sec-
tions sliced at the center of the mamillary body were used for quanti-
tative analysis (n = 4 per group). The number of pyramidal neurons in
the CA3 region was measured manually using digital photomicro-
graphs of H&E-stained preparations.
Electron Microscopy
Transmission EM was performed on 6 month old Tg and nTg litter-
mates after they were deeply anesthetized and sacrificed by transcar-
dial perfusion with 10 ml of 0.1 M cacodylate buffer (pH 7.4) followed
by 50 ml of fixative (2% glutaraldehyde and 2% paraformaldehyde in
0.1 M cacodylate buffer). Samples were prepared and examined
with a JEM-1010 EM (Jeol, Peabody, MA) as described (Zhang et al.,
2004, 2005).
Pre-embedding immuno-EM was performed on brain samples from
Tg and nTg mice, perfusion-fixed as described above, except that
buffer containing 0.2% instead of 2% glutaraldehyde was used. The
brain and the spinal cord from each mouse were removed and post-
fixed in 0.1 M cacodylate buffer containing 4% paraformaldehyde,
0.2% glutaraldehyde, and 0.2% picric acid overnight, and 50 mm sec-
tions were probed with primary anti-tau 17026 (1:500) antibodies as
described (Ishihara et al., 1999; Zhang et al., 2004); this was followed
by development with silver methenamine (Rodriguez et al., 1984).
Antibodies
The following anti-tau antibodies were used in this study: mAb T14
(specific to human tau) (Kosik et al., 1988), mAb T49 (specific to rodent
tau) (Mawal-Dewan et al., 1994); rabbit pAb 17026 (Ishihara et al.,
1999); mAb T1 (Binder et al., 1985), mAb AT8 (Goedert et al., 1994),
mAb PHF1 (Greenberg and Davies, 1990), and mAb AT270 (Goedert
et al., 1994). We also used antibodies to middle molecular weight neu-
rofilament subunit (NFM) and NFL, including mAb ROM 24 to NFM and
rabbit pAb to NFL (Tu et al., 1995); antibodies to a-synuclein including
pAb SNL1 (Giasson et al., 2000) and mAb syn 202 (Giasson et al.,
2000); mAb against a-tubulin (Santa Cruz); mAb against synaptophysin
(Boehringer); pAb specific for GFAP in astrocytes (DAKO); pAb against
IL-1b (Santa Cruz); pAb against cox-2 (Santa Cruz); mAb against cal-
nexin (Stressgen); and mAbs recognizing microglia, including mAbs
against HLA-D (Monozan), HLA-DR (Chemicon), and CD11b (Serotex).
Electrophysiology
Electrophysiology was performed for 6 month old nTg and PS19 mice
as described (Huang et al., 2006). Briefly, mice were deeply anesthe-
tized by intraperitoneal administration of 50mg/kg sodium pentobarbi-
tal and placed on a stereotaxic device. Core body temperature was
monitored and maintained at 35C ± 0.5C via a heating pad. The skull
was exposed and small holes were drilled at the sites where recording
and stimulating electrodes were to be positioned. Glass recording
electrodes (tip resistance of 1–3 megawatts) were filled with saline.
The electrode for the extracellular field potential recording was in-
serted into the stratum radiatum of the CA1 region of hippocampus
(2.2 mm posterior to the bregma, 1.25 mm lateral to the midline, and
1.0–1.5 mm ventral to the brain surface). For stimulation in the CA1 re-
gion, a platinum coaxial bipolar stimulating electrodewas positioned in
the stratum radiatum to stimulate the Schaffer collateral/commissural
pathway (1.5 mm posterior to the bregma, 2.0 mm lateral to midline,
and 1.0–1.5 mm ventral to the brain surface). Stimulus intensity was
adjusted to produce an average fEPSP amplitude of 1 mV that was348 Neuron 53, 337–351, February 1, 2007 ª2007 Elsevier Incnot larger than one-third of the maximum amplitude. For LTP induction
in the CA1 region, one set of four tetanal trains (50 pulses, 100 Hz) with
a 10 s intertrain interval was used. fEPSPs were monitored and ana-
lyzed using a computer-based data acquisition system. The magni-
tude of potentiation was expressed as the percentage of baseline of
the maximal slope of EPSPs. Before recording LTP, we generated
input/output curves by gradually increasing the intensity of the stimu-
lation. We also recorded PPF evoked with an interpulse interval of 30,
50, 100, and 200 ms. The intensity of stimulation for PPF was adjusted
to evoke approximately 1 mV of first fEPSP amplitude.
MRI of Brain Atrophy in PS19 Tg Mice
MRI studies were conducted for nTg and PS19mice at the ages of 6, 9,
and 12 months (n = 5 in each group) using a Bruker AVANCE 400WB
imaging spectrometer with a 250mT/m actively shieldedmicroimaging
gradient insert (Bruker BioSpin GmbH, Ettlingen, Germany) as de-
scribed (Higuchi et al., 2005). Signal excitation and detection were per-
formed by using a 25 mm resonator. Mice were anesthetized with pen-
tobarbital and isoflurane, and T1-weighted 2D gradient-echo (field of
view = 203 20 mm2, matrix dimensions = 2563 256, nominal in-plane
resolution = 78 mm 3 78 mm, slice thickness = 500 mm, TE = 2.5 ms,
TR = 250 ms, flip angle = 85, number of averages = 15, total imaging
time = 16 min) and T2-weighted 3D spin-echo rapid acquisition with
relaxation enhancement (RARE) (field of view = 20 3 20 3 16 mm3,
matrix dimensions = 256 3 512 3 32, nominal resolution = 78 mm 3
39 mm3 500 mm, TE = 6.4 ms, TR = 3000 ms, RARE factor = 64, num-
ber of averages = 4, total imaging time = 104 min) MRI scans were
performed. Specific emphasis was placed on the neocortex and hip-
pocampus in the coronal images (1.0 – 4.0 mm posterior to the
bregma), and regional volumes were determined using PMOD soft-
ware (PMOD Technologies, Zurich, Switzerland).
Quantification of Microglial Activity by Autoradiography
Microglial activation was quantified by autoradiography on parafor-
maldehyde-fixed, frozen brain sections with [3H]DAA1106, a radio-
tracer for peripheral benzodiazepine receptors as described (Zhang
et al., 2003). [3H]DAA1106 was synthesized by o-methylation of its
desmethylated precursor (DAA1123, generously provided by Taisho
Pharmaceutical, Tokyo, Japan) with [3H]methyliodide (specific radio-
activity, 3.15 TBq/mmol; GE Healthcare, Buckinghamshire, UK). The
reaction product was purified by semipreparative HPLC using
a J’sphere ODS-H80 column (YMC, Kyoto, Japan) eluted with 60%
acetonitrile/40% H2O (flow at 6.0 mL/min). The brain sections were
preincubated in 50 mM Tris-HCl buffer (pH 7.4) at room temperature
for 15 min, followed by reaction with 0.5 nM [3H]DAA1106 (radioactive
concentration, 2.4MBq/L) in 50mMTris-HCl buffer (pH 7.4) at 25C for
60min. Nonspecific binding of the radiotracer was also assayed by co-
incubation with 10 mMof PK11195 (Sigma, St. Louis, MO). Radioactive
signals were detected by a BAS-TR2025 imaging plate (Fuji Film,
Tokyo, Japan) and BAS5000 image analyzer (Fuji Film, Tokyo, Japan).
Regional radioactivity corrected for nonspecific radiotracer binding
was determined for the hippocampus and neocortex in the samples
coronally sliced at 2.5 mm posterior to the bregma.
Administration of FK506 to Immunosuppress
Young PS19 Tg Mice
FK506 was given in drinking water (10 ppm of FK506 corresponding
to administration of1 mg/kg per day) to 19 PS19mice from 2months
of age to the time of sacrifice (6 mice at 8 months of age and 6 mice at
12 months of age).
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/53/3/337/DC1/..
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